Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 29Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Melanoma 12Carcinoma, Renal Cell 12Carcinoma, Hepatocellular 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Glioblastoma 11Breast Neoplasms 11Triple Negative Breast Neoplasms 10Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 8Uterine Cervical Neoplasms 7Brenner Tumor 7Mycosis Fungoides 6Colonic Neoplasms 6Brain Neoplasms 6Rectal Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Endometrial Neoplasms 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

Octreotide 4Leucovorin 3Trastuzumab 2Temozolomide 2Oxaliplatin 2Fluorouracil 2Capecitabine 2Bevacizumab 2veliparib 1vatalanib 1tipifarnib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Salts 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vipoma × Immunoglobulin G × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡